Biotech spends $60bn on Chinese drugs; Trump buys Lilly
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- U.S. biotech spent $60 billion on Chinese molecules in the first quarter of 2026, on track to double last year’s total, which was already ten times the 2021 level.
- China’s drug supply is deepening a split among U.S. biotech firms, pitting peers and partners against one another and souring relationships.
- President Trump bought up to $680 k of Eli Lilly stock earlier this year.
- U.S. government disclosed Trump’s stock and bond trades from January to March 2026 on May 14, highlighting the timing of his purchases.
- Eli Lilly’s GLP‑1 drugs moved closer to Medicare reimbursement for weight‑loss treatment after recent government decisions.
Why it matters: Eli Lilly stands to profit from the new Medicare reimbursement pathway for its GLP‑1 weight‑loss drugs, while its stock surge aligns with Trump’s personal investment, underscoring a conflict of interest; simultaneously, the $60 billion Chinese‑drug reliance fuels internal rifts that could hinder a unified biotech strategy.
Ask SkimNews
